Defining the neurotoxin derived illness chronic ciguatera using markers of chronic systemic inflammatory disturbances: A case/control study

Neurotoxicology and Teratology

Volumn 32, Issue 6, 2010, Pages 633-639

  Shoemaker, Ritchie C ^a   House, Dennis ^a   Ryan, James C ^b  

^a Center for Research on Biotoxin Associated Illnesses   (United States)

^b CENTER FOR COASTAL ENVIRONMENTAL HEALTH AND BIOMOLECULAR RESEARCH   (United States)

Author keywords

Biotoxin; Chronic inflammatory response syndrome; Ciguatera fish poisoning; Ciguatoxin; Immune; Inflammation

Indexed keywords

CIGUATOXIN; COMPLEMENT COMPONENT C4A; HLA DR ANTIGEN; INTERMEDIN; NEUROPEPTIDE; NEUROTOXIN; TRANSFORMING GROWTH FACTOR BETA1; VASOACTIVE INTESTINAL POLYPEPTIDE;

ADULT; ANAMNESIS; ARTICLE; CASE CONTROL STUDY; CHRONIC DISEASE; CHRONIC INFLAMMATION; CIGUATERA; CONTRAST SENSITIVITY; CONTROLLED STUDY; FEMALE; GENETIC MARKER; GENOTYPE; HUMAN; IMMUNOPATHOLOGY; INNATE IMMUNITY; INTOXICATION; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYMPTOM; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHRONIC DISEASE; CIGUATERA POISONING; CIGUATOXINS; CONTRAST SENSITIVITY; DIAGNOSIS, DIFFERENTIAL; HUMANS; MIDDLE AGED; NEUROTOXINS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

CIGUATERA; DINOPHYCEAE;

EID: 77956886186     PISSN: 08920362     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ntt.2010.05.007     Document Type: Article

References (55)

1. Amara U., Rittirsch D., Flierl M., Bruckner U., Klos A., Gebhard F., Lambris J.D., Huber-Lang M. Interaction between the coagulation and complement system. Adv. Exp. Med. Biol. 2008, 632:71-79.
2. Antoniades C.G., Berry P.A., Wendon J.A., Vergani D. The importance of immune dysfunction in determining outcome in acute liver failure. J. Hepatol. 2008, 49:845-861.
3. Bagnis R. Ciguatera, sante et developpement en Polynesie francaise. Unión Méd. Can. 1986, 115:502-506.
4. Bianchi M.E. DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol. 2007, 81:1-5.
5. Blanchong C.A., Chung E.K., Rupert K.L., Yang Y., Yang Z., Zhou B., Moulds J.M., Yu C.Y. Genetic, structural and functional diversities of human complement components C4A and C4B and their mouse homologues, Slp and C4. Int. Immunopharmacol. 2001, 1:365-392.
6. Bossart G.D., Baden D.G., Ewing R.Y., Roberts B., Wright S.D. Brevetoxicosis in manatees (Trichechus manatus latirostris) from the 1996 epizootic: gross, histologic, and immunohistochemical features. Toxicol. Pathol. 1998, 26:276-282.
7. Boydron-Le Garrec R., Benoit E., Sauviat M.P., Lewis R.J., Molgo J., Laurent D. Ability of some plant extracts, traditionally used to treat ciguatera fish poisoning, to prevent the in vitro neurotoxicity produced by sodium channel activators. Toxicon 2005, 46:625-634.
8. Brzoska T., Luger T.A., Maaser C., Abels C., Bohm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr. Rev. 2008, 29:581-602.
9. Bulens C., Meerwaldt J.D., Van der Wildt G.J. Effect of stimulus orientation on contrast sensitivity in Parkinson's disease. Neurology 1988, 38:76-81.
10. Carrithers M.D., Dib-Hajj S., Carrithers L.M., Tokmoulina G., Pypaert M., Jonas E.A., Waxman S.G. Expression of the voltage-gated sodium channel NaV1.5 in the macrophage late endosome regulates endosomal acidification. J. Immunol. 2007, 178:7822-7832.
11. Chaudhury D., Loh D.H., Dragich J.M., Hagopian A., Colwell C.S. Select cognitive deficits in vasoactive intestinal peptide deficient mice. BMC Neurosci. 2008, 9:63.
12. Costa M.F., Tomaz S., de Souza J.M., Silveira L.C., Ventura D.F. Electrophysiological evidence for impairment of contrast sensitivity in mercury vapor occupational intoxication. Environ. Res. 2008, 107:132-138.
13. Craner M.J., Damarjian T.G., Liu S., Hains B.C., Lo A.C., Black J.A., Newcombe J., Cuzner M.L., Waxman S.G. Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. Glia 2005, 49:220-229.
14. Danke N.A., Koelle D.M., Yee C., Beheray S., Kwok W.W. Autoreactive T cells in healthy individuals. J. Immunol. 2004, 172:5967-5972.
15. Dechraoui M.Y., Tiedeken J.A., Persad R., Wang Z., Granade H.R., Dickey R.W., Ramsdell J.S. Use of two detection methods to discriminate ciguatoxins from brevetoxins: application to great barracuda from Florida Keys. Toxicon 2005, 46:261-270.
16. Delgado M., Ganea D. Anti-inflammatory neuropeptides: a new class of endogenous immunoregulatory agents. Brain Behav. Immun. 2008, 22:1146-1151.
17. Fleming L.E., Broad K., Clement A., Dewailly E., Elmir S., Knap A., Pomponi S.A., Smith S., Solo Gabriele H., Walsh P. Oceans and human health: emerging public health risks in the marine environment. Mar. Pollut. Bull. 2006, 53:545-560.
18. Fraser S.P., Diss J.K.J., Lloyd L.J., Pani F., Chioni A.-M., George A.J.T., Djamgoz M.B.A. T-lymphocyte invasiveness: control by voltage-gated Na+ channel activity. FEBS Lett. 2004, 569:191-194.
19. Gong Y., Kishi R., Kasai S., Katakura Y., Fujiwara K., Umemura T., Kondo T., Sato T., Sata F., Tsukishima E., et al. Visual dysfunction in workers exposed to a mixture of organic solvents. Neurotoxicology 2003, 24:703-710.
20. Gonzalez-Gay M.A., Garcia-Porrua C., Hajeer A.H. Influence of human leukocyte antigen-DRB1 on the susceptibility and severity of rheumatoid arthritis. Semin. Arthritis Rheum. 2002, 31:355-360.
21. Gozes I., Bardea A., Bechar M., Pearl O., Reshef A., Zamostiano R., Davidson A., Rubinraut S., Giladi E., Fridkin M., et al. Neuropeptides and neuronal survival: neuroprotective strategy for Alzheimer's disease. Ann. NY Acad. Sci. 1997, 814:161-166.
22. Harfouch-Hammoud E.I., Daher N.A. Susceptibility to and severity of tuberculosis is genetically controlled by human leukocyte antigens. Saudi Med. J. 2008, 29:1625-1629.
23. Hokama Y., Uto G.A., Palafox N.A., Enlander D., Jordan E., Cocchetto A. Chronic phase lipids in sera of chronic fatigue syndrome (CFS), chronic ciguatera fish poisoning (CCFP), hepatitis B, and cancer with antigenic epitope resembling ciguatoxin, as assessed with MAb-CTX. J. Clin. Lab. Anal. 2003, 17:132-139.
24. Imamura Y., Yokoyama T., Takesue Y., Hiyama E., Sueda T. The TH1/TH2 ratio in patients with diminished expression of HLA-DR on monocytes. Int. Congress Ser. 2003, 1255:225-229.
25. Kriegel M.A., Li M.O., Sanjabi S., Wan Y.Y., Flavell R.A. Transforming growth factor-beta: recent advances on its role in immune tolerance. Curr. Rheumatol. Rep. 2006, 8:138-144.
26. Lehane L., Lewis R.J. Ciguatera: recent advances but the risk remains. Int. J. Food Microbiol. 2000, 61:91-125.
27. Lewis R.J. The changing face of ciguatera. Toxicon 2001, 39:97-106.
28. Magnoni S., Stocchetti N., Colombo G., Carlin A., Colombo A., Lipton J.M., Catania A. Alpha-melanocyte-stimulating hormone is decreased in plasma of patients with acute brain injury. J. Neurotrauma 2003, 20:251-260.
29. Makinde T., Murphy R.F., Agrawal D.K. The regulatory role of TGF-[beta] in airway remodeling in asthma. Immunol. Cell Biol. 2007, 85:348-356.
30. M. Matsui, S. Kumar-Roine, H.T. Darius, M. Chinain, D. Laurent, S. Pauillac, Pacific ciguatoxin 1B-induced modulation of inflammatory mediators in a murine macrophage cell line, Toxicon In Press, doi:10.1016/j.toxicon.2009.05.039.
31. Matta J., Navas J., Milad M., Manger R., Hupka A., Frazer T. A pilot study for the detection of acute ciguatera intoxication in human blood. J. Toxicol. Clin. Toxicol. 2002, 40:49-57.
32. Montano-Loza A.J., Carpenter H.A., Czaja A.J. Clinical significance of HLA DRB103-DRB104 in type 1 autoimmune hepatitis. Liver Int. 2006, 26:1201-1208.
33. Morey J.S., Ryan J.C., Bottein Dechraoui M.Y., Rezvani A.H., Levin E.D., Gordon C.J., Ramsdell J.S., Van Dolah F.M. Liver genomic responses to ciguatoxin: evidence for activation of phase I and phase II detoxification pathways following an acute hypothermic response in mice. Toxicol. Sci. 2008, 103:298-310.
34. Mugridge K.G., Perretti M., Ghiara P., Parente L. Alpha-melanocyte-stimulating hormone reduces interleukin-1 beta effects on rat stomach preparations possibly through interference with a type I receptor. Eur. J. Pharmacol. 1991, 197:151-155.
35. Oppenheim J., Tewary P., de la Rosa G., Yang D. Alarmins initiate host defense. Immune-mediated Diseases 2007, 185-194. Springer New York, New York. M. Shurin, Y. Smolkin (Eds.).
36. Osafo-Addo A.D., Koram K.A., Oduro A.R., Wilson M., Hodgson A., Rogers W.O. HLA-DRB1*04 allele is associated with severe malaria in northern Ghana. Am. J. Trop. Med. Hyg. 2008, 78:251-255.
37. Pearn J. Models for the chronic fatigue syndrome: channelopathies and ciguatera. The Clinical and Scientific Basis of Chronic Fatigue Syndrome: From Myth towards Management 1998, Sydney. T.K. Robers (Ed.).
38. Peerschke E.I., Yin W., Ghebrehiwet B. Platelet mediated complement activation. Adv. Exp. Med. Biol. 2008, 632:81-91.
39. Porter R. Complement polymorphism, the major histocompatibility complex and associated diseases: a speculation. Mol. Biol. Med. 1983, 1:161-168.
40. Ram M., Sherer Y., Shoenfeld Y. Matrix metalloproteinase-9 and autoimmune diseases. J. Clin. Immunol. 2006, 26:299-307.
41. Rittirsch D., Flierl M.A., Ward P.A. Harmful molecular mechanisms in sepsis. Nat. Rev. Immunol. 2008, 8:776-787.
42. Roselli F., Livrea P., Jirillo E. Voltage-gated sodium channel blockers as immunomodulators. Recent Pat. CNS Drug Discov. 2006, 1:83-91.
43. Ryan J.C., Bottein Dechraoui M.Y., Morey J.S., Rezvani A., Levin E.D., Gordon C.J., Ramsdell J.S., Van Dolah F.M. Transcriptional profiling of whole blood and serum protein analysis of mice exposed to the neurotoxin Pacific Ciguatoxin-1. Neurotoxicology 2007, 28:1099-1109.
44. Schnorf H., Taurarii M., Cundy T. Ciguatera fish poisoning: a double-blind randomized trial of mannitol therapy. Neurology 2002, 58:873-880.
45. Shoemaker R.C. Residential and recreational acquisition of possible estuary-associated syndrome: a new approach to successful diagnosis and treatment. Environ. Health Perspect. 2001, 109(Suppl 5):791-796.
46. Shoemaker R.C. Sick Building Syndrome in Water-damaged Buildings: Generalization of the Chronic Biotoxin-associated Illness Paradigm to Indoor Toxigenic Fungi 2005, 66-77. Bioaerosols, Fungi, Bacteria, Mycotoxins and Human Health, Fungal Research Group Foundation, Albany, NY. E. Johanning (Ed.).
47. Shoemaker R.C., Giclas P.C., Crowder C., House D., Glovsky M.M. Complement split products C3a and C4a are early markers of acute lyme disease in tick bite patients in the United States. Int. Arch. Allergy Immunol. 2008, 146:255-261.
48. Shoemaker R.C., House D.E. Sick building syndrome (SBS) and exposure to water-damaged buildings: time series study, clinical trial and mechanisms. Neurotoxicol. Teratol. 2006, 28:573-588.
49. Steere A.C., Klitz W., Drouin E.E., Falk B.A., Kwok W.W., Nepom G.T., Baxter-Lowe L.A. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J. Exp. Med. 2006, 203:961-971.
50. Sun W., Hong J., Zang Y.C., Liu X., Zhang J.Z. Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis. Int. Immunol. 2006, 18:1691-1700.
51. Tan Y.-R., Yang T., Liu S.-P., Xiang Y., Qu F., Liu H.-J., Qin X.-Q. Pulmonary peptidergic innervation remodeling and development of airway hyperresponsiveness induced by RSV persistent infection. Peptides 2008, 29:47-56.
52. Tschoeke S.K., Ertel W. Immunoparalysis after multiple trauma. Injury 2007, 38:1346-1357.
53. Van Lint P., Libert C. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J. Leukoc. Biol. 2007, 82:1375-1381.
54. Wallis R., Dodds A.W., Mitchell D.A., Sim R.B., Reid K.B., Schwaeble W.J. Molecular interactions between MASP-2, C4, and C2 and their activation fragments leading to complement activation via the lectin pathway. J. Biol. Chem. 2007, 282:7844-7851.
55. Yadav M., Rosenbaum J., Goetzl E.J. Cutting edge: vasoactive intestinal peptide (VIP) induces differentiation of Th17 cells with a distinctive cytokine profile. J. Immunol. 2008, 180:2772-2776.